SNDX · CIK 0001395937
What Syndax Pharmaceuticals, Inc. told the SEC could break it.
1 self-disclosed vulnerability, pulled from its own filings — each in the company’s words, with the source. This is the risk register almost nobody reads.
A limited set so far — we surface every cited disclosure we’ve extracted for SNDX. More may follow as additional filings are processed.
In its own words
What could break it.
Supplier concentration
- No in-house manufacturing — relies on a limited number of contract manufacturers (and partner Incyte) for all raw materials, API and finished product; commercial-manufacturing concentrationmedium
Syndax owns no manufacturing facilities for revumenib (Revuforj), axatilimab (Niktimvo) or entinostat and has no plans to build them. It relies entirely on third-party contract manufacturers — and on its partner Incyte — for all required raw materials, active pharmaceutical ingredients and finished product across preclinical, clinical and commercial supply, and it relies on a limited number of API suppliers, giving it explicit concentration risk in commercial manufacturing. With newly commercial products (Revuforj net revenue $124.8M in 2025) dependent on this outsourced, concentrated, single/limited-source chain, a supplier failure, quality issue or capacity shortfall could interrupt commercial supply. A genuine sole-source/manufacturing-concentration dependence (the Incyte supply relationship is also captured as an edge).
“the Company currently relies on a limited number of suppliers for the active pharmaceutical ingredients in its products. Accordingly, the Company has concentration risk associated with its commercial manufacturing.”
SEC filing →As of 2026
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings — including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its customers
“Incyte leads the commercialization of axatilimab globally and we are co-commercializing Niktimvo in the United States.”
Cited →“We and Syndax have agreed to co-develop axatilimab and to share development costs associated with global and U.S.-specific clinical trials, with Incyte responsible for 55 % of such costs and Syndax responsible for 45 % of such costs.”
Cited →
Its suppliers
“We currently rely on third-party contract manufacturers as well as Incyte for all of our required raw materials, active pharmaceutical ingredients and finished product for our preclinical research, clinical trials, and commercial supply.”
Cited →
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch